

## **Appendix 1**

### **Interview Guide**

1. Please describe your responsibilities at your organization/please describe your engagement with anti-corruption.
2. Please provide some background information on policies and procedures with regard to anti-corruption within the WHO, the UNDP, the World Bank, and/or the Global Fund.
  - a. Prompts:
    - i. Can you describe the stakeholders involved?
    - ii. What sort of evaluation methods are in place to measure the impact of these policies/procedures?
    - iii. What sort of evidence exists pertaining to the efficacy of anti-corruption, transparency, and accountability (ACTA) measures employed by your institution?
    - iv. What are the strengths and weaknesses of your organization's approach to ACTA?
    - v. What specific measures (policies or procedures) exist in relation to the health and pharmaceutical sectors?
    - vi. Is there a specific example of your organization's use of ACTA measures?
3. How have the ACTA policies and procedures progressed over time?
4. How have the ACTA policies and procedures changed during the COVID-19 pandemic?
5. Please describe facilitators/barriers to implementing ACTA within organizations and amongst country beneficiaries.
  - a. Can you speak to how these have changed as a result of COVID-19?
6. Moving forward, what could be done to improve the efficacy of ACTA measures?
7. How is your organization bound by the UNCAC? i.e. how much of your work is institutional policy vs. how much is constrained by UNCAC
8. Are there specific documents about ACTA measures in your organization that you think we should look at?
9. Is there any information that you feel is relevant that you would like to add to this discussion?
10. Can you please provide us with at least 2 names of individuals, either who work for the same organization as you or not, who could provide us with more information on the topic of ACTA?

## **Appendix 2**

### **Codes used in qualitative thematic analysis**

- Barriers to implementation of anti-corruption initiatives
- Changes in approaches to anti-corruption
- COVID-19

- Collaboration
- Technology
- Examples and case studies
- Strengths
- Weaknesses
- Background information
- Recommendations
- Health and pharmaceuticals
- Facilitators of implementation
- Impact
- Definition of corruption
- Shift to prevention
- Anticipated trajectory
- Monitoring and evaluation
- Approach to anti-corruption
- Transparency
- Accountability
- Governance

### **Appendix 3**

#### **Themes (created based on the codes in Appendix 2) used in qualitative thematic analysis**

1. Approaches to anti-corruption
  - a. Shift to prevention
2. Strengths of approaches to anti-corruption
3. Facilitators of implementing anti-corruption initiatives
4. Weaknesses of approaches to anti-corruption
5. Anticipated trajectory of anti-corruption initiatives
  - a. COVID-19